Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease.
Cristiana-Elena VladLiliana Georgeta FoiaRoxana PopescuIuliu IvanovMihaela Catalina LucaCarmen DelianuVasilica TomaCristian StatescuCiprian RezusLaura FloreaPublished in: Journal of diabetes research (2019)
Although the "dyslipidemic status" in CKD/ESRD is not clearly depicted, due to different research findings, ApoA-I, ApoA-IV, and ApoB/ApoA-I ratio could be predictors of cardiovascular risk. Serum PCSK9 levels were not associated with the cardiovascular events in patients with CKD/ESRD. Probably in the future, the treatment of dyslipidemia in CKD/ESRD will be aimed at discovering new effective therapies on the action of these biomarkers.